ClinicalTrials.Veeva

Find clinical trials for Eczema in New York, NY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Dyssomnias
Parasomnias
Food Hypersensitivity
Hypersensitivity
Psoriasis

Eczema trials near New York, NY, USA:

Topical Ruxolitinib Evaluation in Chronic Hand Eczema

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema...

Active, not recruiting
Hand Eczema
Drug: Ruxolitinib cream
Drug: Vehicle

Phase 2

Incyte
Incyte

New York, New York, United States and 35 other locations

Locations recently updated

The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. Th...

Enrolling
Atopic Hand Eczema
Atopic Dermatitis
Drug: Tralokinumab
Drug: Placebo

Phase 3

LEO Pharma
LEO Pharma

New York, New York, United States and 53 other locations

The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema...

Enrolling
Atopic Eczema
Moderate-to-Severe Atopic Dermatitis
Other: Topical emollient (moisturizer)
Drug: dupilumab

Phase 4

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

New York, New York, United States and 29 other locations

This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 52 weeks by subjects with atopic dermatitis (eczema)....

Active, not recruiting
Atopic Dermatitis Eczema
Drug: ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%

Phase 3

Arcutis Biotherapeutics
Arcutis Biotherapeutics

Kew Gardens, New York, United States and 91 other locations

The study is trying to answer the following question: "Can we use non-invasive imaging to evaluate the response of atopic dermatitis (eczema...

Enrolling
Eczema
Atopic Dermatitis
Device: Reflectance confocal microscopy
Drug: Dupilumab

Phase 4

OptiSkin Medical

New York, New York, United States

the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo.OpSCF or placebo will be adm...

Active, not recruiting
Atopic Dermatitis
Biological: OpSCF
Biological: Placebo

Phase 2

Opsidio

Kew Gardens, New York, United States of America and 21 other locations

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab

Phase 3

Lilly
Lilly

New York, New York, United States and 41 other locations

The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atop...

Enrolling
Atopic Dermatitis
Drug: Lebrikizumab

Phase 3

Lilly
Lilly

New York, New York, United States and 47 other locations

This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atop...

Enrolling
Atopic Dermatitis
Drug: ADX-914
Drug: Placebo

Phase 2

Q32 Bio

Hackensack, New Jersey, United States and 39 other locations

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Other: Placebo
Drug: PF-07264660

Phase 2

Pfizer
Pfizer

New York, New York, United States and 40 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems